A 42-year-old woman with systemic lupus erythematosus on NSAIDs and ACE inhibitor presents with serum potassium 6.2 mEq/L, normal renal function (eGFR 65 mL/min/1.73m²), and asymptomatic. ECG is normal. Which investigation is most appropriate to differentiate transcellular shift from true total body potassium excess?

Explanation

## Differentiating Transcellular Shift from True Total Body Potassium Excess **Key Point:** Urine potassium concentration and 24-hour urine potassium excretion are the most appropriate investigations to differentiate transcellular shift (no change in total body K⁺) from true total body potassium excess (increased renal K⁺ excretion or impaired excretion). ### Pathophysiological Basis Hyperkalemia arises from two broad mechanisms: 1. **Transcellular shift** — K⁺ moves from intracellular to extracellular space (e.g., acidosis, insulin deficiency, cell lysis, beta-blockade). Total body K⁺ is **normal**. 2. **True total body K⁺ excess** — excess intake or impaired renal excretion (e.g., ACE-I/NSAID-induced hypoaldosteronism, renal failure). Total body K⁺ is **elevated**. ### Why Urine Potassium Excretion is the Correct Answer | Finding | Interpretation | |---|---| | **Low urine K⁺ (< 20 mEq/L or < 20 mEq/day)** | Renal K⁺ retention → impaired excretion (ACE-I, NSAID effect) OR transcellular shift (kidneys appropriately conserving K⁺ is not the issue — shift is) | | **High urine K⁺ (> 40 mEq/L or > 40 mEq/day)** | Kidneys excreting excess K⁺ → dietary excess or renal K⁺ wasting | In **transcellular shift**, the kidneys respond normally and urine K⁺ excretion is **low** (< 20 mEq/day) because total body K⁺ is not elevated. In **true excess**, urine K⁺ is either high (dietary/renal wasting) or inappropriately low (impaired excretion). This distinction is made by **24-hour urine K⁺ excretion**, the gold standard for quantifying renal K⁺ handling (Harrison's Principles of Internal Medicine, 21st ed.). ### Why Other Options Are Less Appropriate - **Option B (Serum osmolality + ABG):** ABG helps identify acidosis as a cause of shift but does NOT quantify total body K⁺ status or renal handling. - **Option C (Plasma renin + aldosterone):** Useful to diagnose hypoaldosteronism (relevant here given ACE-I use) but does NOT directly differentiate transcellular shift from total body excess. - **Option D (TTKG):** TTKG assesses renal tubular K⁺ secretory capacity and is useful for diagnosing renal vs. extrarenal causes, but it has significant limitations — it requires urine osmolality > plasma osmolality to be valid, and its clinical utility has been questioned in modern nephrology literature (Kamel & Halperin, CJASN 2012). Crucially, TTKG does **not** directly quantify total body K⁺ status. ### Clinical Application in This Patient This patient on ACE-I + NSAIDs (both suppress aldosterone) may have impaired renal K⁺ excretion. A **low 24-hour urine K⁺** would suggest impaired excretion (true retention) or transcellular shift, while a **high urine K⁺** would suggest dietary excess. Combined with clinical context (ABG for acidosis), urine K⁺ excretion best answers the specific question asked. **High-Yield:** 24-hour urine K⁺ < 20 mEq/day in the setting of hyperkalemia = transcellular shift or impaired renal excretion; > 40 mEq/day = dietary excess or renal K⁺ wasting (Harrison's, 21st ed.). **Clinical Pearl:** TTKG is a teaching tool for understanding tubular physiology but urine K⁺ excretion (spot or 24-hour) remains the practical bedside investigation to assess total body K⁺ balance.